Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma.

PubWeight™: 0.91‹?›

🔗 View Article (PMC 3246694)

Published in Dermatol Res Pract on December 15, 2011

Authors

Felipe Ades1, Otto Metzger-Filho

Author Affiliations

1: Department of Dermatology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 948005 Villejuif, France.

Associated clinical trials:

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | NCT01037127

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain (Break MB) | NCT01266967

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

The phosphoinositide 3-kinase pathway. Science (2002) 24.72

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Melanoma biology and new targeted therapy. Nature (2007) 10.71

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53

The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82

Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76

Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98

Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 3.79

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58

PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol (2004) 3.57

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98

Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58

The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol (1999) 2.57

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18

eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res (2011) 2.10

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07

Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98

RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol (2011) 1.92

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet (2005) 1.90

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 1.86

Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res (2005) 1.84

High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer (2004) 1.79

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem (2001) 1.72

Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66

Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res (2003) 1.58

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46

Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev (2005) 1.46

Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res (2004) 1.38

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer (2011) 1.33

Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol (2009) 1.32

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer (2005) 1.30

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer (2009) 1.30

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer (2010) 1.24

Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc (2001) 1.23

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med (2005) 1.22

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21

Metastatic melanoma: chemotherapy. Semin Oncol (2002) 1.20

BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol (2004) 1.16

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer (2010) 1.16

Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs (2005) 1.13

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology (2009) 1.12

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer (2003) 1.11

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07

Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer (2009) 1.05

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol (2001) 1.05

Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer (2008) 1.01

FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.01

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med (2012) 0.97

Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol (2010) 0.93

ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspect (2008) 0.92

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol (2008) 0.87

Gastrointestinal stromal tumors: the histology report. Dig Liver Dis (2011) 0.87

Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Melanoma Res (2010) 0.84

DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine. Cancer Treat Rep (1980) 0.82

A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR. J Mol Model (2011) 0.80

[mTOR, the mammalian target of rapamycin]. Med Sci (Paris) (2010) 0.78

E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission. Clin Adv Hematol Oncol (2007) 0.76

Articles by these authors

The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev (2013) 1.73

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol (2013) 1.62

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol (2012) 1.03

Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast (2011) 0.98

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat (2012) 0.95

Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs (2012) 0.92

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer (2013) 0.88

Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf (2012) 0.84

Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79

Changing the clinical picture of challenging tumors: tales becoming reality? Future Oncol (2009) 0.75